Sinew Pharma, Inc.
TTPEX:663455.40
TWD
-2.30
(-3.99%)
ISIN
TW0006634009
Return %
Stock
S&P 500
1Y
23.11
14.20
3Y
-17.07
81.12
5Y
-14.64
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Kai Min Zhu
- Full Time Employees
- 57
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- C516, Building C Taipei TP Taiwan 11571
- IPO Date
- Jun 29, 2017
- Website
- sinewpharma.com
- Similar Companies
- Business
- Sinew Pharma Inc. is a Taiwan-based biopharmaceutical company specializing in the development and commercialization of innovative drugs addressing unmet medical needs, particularly in metabolic dysfunction-associated steatohepatitis (MASH) and hepatotoxicity-free analgesics. The company’s core products include several late-stage drug candidates: SNP-610, an innovative combination drug in Phase II clinical trials targeting alcoholic steatohepatitis and MASH; SNP-630, a new chemical entity in Phase II for related indications; SNP-810, a next-generation acetaminophen with high liver safety undergoing Phase II trials for pain relief and fever reduction; SNP-820, an acetaminophen poisoning antidote in Phase II; and preclinical candidates SNP-830 and SNP-840, developed as hepatotoxicity-free analgesics for the U.S. market. These products emphasize safety improvements over conventional acetaminophen to reduce liver injury risks. Sinew Pharma serves global markets with a focus on Taiwan and the U.S., providing pharmaceutical solutions for liver diseases, pain management, and related conditions. Founded in 2014 and headquartered in Taipei City, Taiwan, Sinew Pharma operates as a publicly listed company on the Taiwan Stock Exchange (Ticker: 6634.TWO). The company has recently advanced its clinical pipeline significantly, notably achieving primary and secondary endpoints in Phase I/II trials for SNP-810, a novel pain relief drug with enhanced liver safety, positioning it to capture a market opportunity valued at $950 million. Additionally, Sinew Pharma actively participates in major industry events such as the MASH Drug Development Summit, presenting new research findings to strengthen its profile in MASH treatment development. The company also announced strategic progress in developing first-in-class treatments for liver-related diseases, emphasizing its role in pioneering hepatotoxicity-free analgesic drugs and MASH therapeutics. Sinew Pharma’s business model integrates research, clinical development, and commercialization of pharmaceutical products addressing critical health issues related to liver toxicity and pain management. Its product pipeline and R&D efforts reflect a strategic focus on innovative, safer alternatives to existing therapies, primarily through novel chemical entities and combination drugs. The company maintains a portfolio targeting non-alcoholic steatohepatitis (NASH, now termed MASH), liver cirrhosis, liver cancer, and pain/fever reduction with minimal hepatotoxic risk. This strategy aims to serve patients suffering from severe liver injuries linked to conventional drugs, capitalizing on robust market demand and expanding therapeutic indications. In the last 1-2 years, Sinew Pharma has notably advanced clinical trials for its key pipeline drugs, including SNP-810, and expanded its presence in global markets through participation in international summits and showcasing its research breakthroughs. The company pursues collaborations and strategic alliances to enhance its drug development capabilities and market penetration. Its commitment to innovation in hepatotoxicity-free drugs distinguishes it within the biopharmaceutical industry focused on liver health and analgesic safety. Sinew Pharma’s leadership includes Chairman and CEO Kaimin Chu, supported by an experienced management and scientific advisory team guiding the company’s R&D and strategic direction. The company’s operations and drug development are centered in Taiwan, with an increasing emphasis on clinical collaborations and regulatory approvals extending toward the U.S. and other global markets. This positions Sinew Pharma as a leading pharmaceutical innovator addressing urgent unmet medical needs with a comprehensive pipeline of liver safety-focused therapeutics.